Navigation Links
Idiopathic pulmonary fibrosis (IPF) community emphasizes the power of united support for patients during IPF World Week 2013
Date:9/19/2013

BRISBANE, Calif., Sept. 20, 2013 /PRNewswire/ -- This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time of two to five years,i and their families calling for an integrated approach to further strengthen the national and international network of people working to support patients with this fatal orphan lung disease.  The fundamental aim is to lessen patients' isolation and fear by demonstrating that there is a growing community of support.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

This year's campaign theme of the awareness week, which was founded only two years ago in order to address the issue that people with the disease felt overlooked, is 'Breath of Hope'.  In Europe, around one hundred initiatives will take place in IPF centers of excellence, which will involve IPF experts, patients and wider communities.  In the United States many initiatives are taking place during IPF World Week, some of which have extended throughout the month of September, driven by two leading patient associations, the Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF).

"IPF is a serious and rare illness and by being a rare and poorly understood disease, patients often feel secluded and alone.  There is a European network of IPF patient advocacy groups working to support patients and their families. We must bring hope to those who live with IPF and show that their needs are now being better recognized. This year, images representing the 'Breath of Hope' campaign were selected by European, American and Canadian IPF associations through an international public photo and video competition. The two winning images represent support across generat
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
2. Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
3. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
4. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
5. FDA Advisory Committee Unanimously Recommends Approval Of Bayers Riociguat In Two Pulmonary Hypertension Indications
6. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
7. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
8. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
9. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
10. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
11. MD Buylines User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: ... site investigator at Emory University, presented long-term follow up ... neural stem cells in the treatment of amyotrophic lateral ... presentation, which occurred at the Annual Symposium on ALS ... , on Friday, and was not open to ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... very familiar "lub-dub" pattern that speeds up or slows ... itself isn,t as regular as you might think. In ... even at a "constant" heart rateand that variability, doctors ... heart rate variability (HRV) has been found to be ... heart failure and inflammation. For athletes, a drop in ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Medical ... for a three-day conference to discuss brain-related diseases ... injury from concussions and neurodegenerative disorders. , ... director affiliated with a Silverado memory care community ... dedicated expertise in memory care, hosts the annual ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... for delivering,albuterol, a fast-acting bronchial dilator, currently use propellants ... beginning December 31st,2009, or replacement HFA,s. Both propellants are ... at near-supersonic speeds. , ... stream of air by ejecting,the medication from a microfluidic ...
... of,Dermatology (Academy) today issued a statement in response to the ... the,relationship between the use of indoor tanning devices and development ... was submitted pursuant to Section,230 of the Food and Drug ... "The American Academy of Dermatology is pleased that ...
... University Medical Center and 10 other healthcare facilities in the ... from the National Institutes of Health to identify which rehabilitation ... traumatic brain injuries. Rush is the only center in Illinois ... this study is to isolate individual components of the range ...
... a disease that includes the buildup of fatty, ... is the underlying cause of heart attacks and strokes. ... has now demonstrated that a receptor for prostaglandin-E2 plays ... findings, reported this month in Cell Metabolism , ...
... 15 Aurora Health Care announced today that,the ... in southeastern Wisconsin, have chosen to join Aurora Medical Group. ... Lakes radiologists practice chiefly at Aurora hospitals and,clinics. , ... every day contribute to the quality,of the care we provide ...
... based data profiling, In-Stream profiling, data quality and MDM discovery solutions ... Migration Alliance (MMA), joining Microsoft Corp. and other key industry partners ... mainframe onto the Microsoft® platform. , ... Chicago, IL ...
Cached Medicine News:Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:American Academy of Dermatology Issues Statement on FDA Report to Congress About Labeling Information on Indoor Tanning Devices 2Health News:Study to identify best rehabilitation therapies for patients with traumatic brain injuries 2Health News:Prostaglandin receptor key to atherosclerosis development 2Health News:Prostaglandin receptor key to atherosclerosis development 3Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 3
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: